Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, single-arm post-authorization pragmatic trial of Xyntha in Chinese subjects with hemophilia A
2015-005040-33Phase 4
- Sponsor
- Pfizer
- Start
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recombinant coagulation factor viii in hemophilia A, sponsored by Pfizer. Primary endpoint: Factor VIII inhibitor development.
02
Drugs
recombinant coagulation factor viii
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2015-005040-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005040-33.